

COMPANY REGISTRATION NUMBER: 07264864

PELICAN CANCER FOUNDATION

FINANCIAL STATEMENTS

FOR THE YEAR ENDED

31 MARCH 2017



CHARITY NUMBER 1141911

taylorcocks

26-32 Oxford Road
Bournemouth
United Kingdom
BH8 8EZ

PELICAN CANCER FOUNDATION

CHARITY INFORMATION

FOR THE YEAR ENDED 31 MARCH 2017

Trustees	Sir Peter Michael CBE (Chairman) Professor R Heald CBE B Moran M Rees G C S Mather M V Morris <i>resigned 1st April 2017</i> J Wood R King S Arnold F Mohamed D Fielding W Boyd <i>appointed 11th April 2017</i>
Charity registration number	1141911
Company number	07264864
Charity address	The Pelican Cancer Foundation The Ark Dinwoodie Drive Basingstoke Hampshire RG24 9NN
Auditors	tgs taylorcocks 3 Acorn Business Centre Northharbour Road Cosham Portsmouth PO6 3TH
Bankers	CAF Bank 25 Kings Hill Avenue Kings Hill West Malling Kent Barclays Bank Plc Market Place Basingstoke Hampshire

PELICAN CANCER FOUNDATION
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2017

CONTENTS	PAGE
Trustees' report	1-6
Auditors' report	7-8
Statement of financial activities	9
Balance sheet	10
Notes to the financial statements	11-21

THE PELICAN CANCER FOUNDATION
TRUSTEES REPORT
FOR THE YEAR ENDED 31 MARCH 2017

The Trustees are pleased to present their report with the audited financial statements of the Charity for the year ended 31 March 2017.

The financial statements comply with the statutory requirements, the Trust Deed and the Statement of Recommended Practice - Accounting and Reporting by Charities (FRS 102) issued on 16 July 2014.

INTRODUCTION

Established in 1993, as the Basingstoke Bowel Cancer Project, the Charity became The Pelican Cancer Foundation in 2000. Pelican was formed to advance greater understanding and treatment of bowel cancer.

Pelican is about helping today's bowel and urology cancer patients live better for longer through research and education initiatives to advance precision treatment.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Charity incorporated in 2013 and the new Charity number is 1141911 (England and Wales) and the company number is 7264864 (England).

The Trustee board, who are also directors of the company, provide the strategic direction for the Charity with authority delegated to the Chief Executive Officer, Mrs. Sarah Crane, for the overall management and administration of the Charity.

The Board appoints Trustees when necessary to meet the changing demands of the Charity. Appropriate induction briefings and training are available for newly appointed trustees.

The full Board of Trustees meets at least twice a year;

In spring - to confirm the strategic aim and agree budget projection/allocation for the coming financial year, review risk.

In autumn - to accept audited accounts, annual report, risk assessment, to monitor in year activity and recommendations from the Research Review Panel.

The Trustee Board may meet at other times as necessary and the Chief Executive regularly meets with the Chairman of Trustees and individual Trustees.

Trustees

Sir Michael, CBE	Chair
Professor R Heald, CBE	Professor of Surgery
Mr B Moran	Colorectal Surgeon
Mr M Rees	Hepatobiliary Surgeon and Clinical Director of Surgery
Mr G Mather	Lawyer
Mr M Morris	Accountant
Mr J Wood	Retired Businessman
Mr R King	Businessman
Mr S Arnold	Colorectal Surgeon
Mr F Mohamed	Colorectal Surgeon
Ms D Fielding	Director Marketing

THE PELICAN CANCER FOUNDATION
TRUSTEES REPORT
FOR THE YEAR ENDED 31 MARCH 2017

The Charity has a scientific advisory board known as the Pelican Research Review Panel (PRRP) which helps direct the research activity, review all research applications and maintain oversight of existing research.

Medical Research Governance

Lord Ribeiro, CBE FRCS	Chair
Professor M Waterfield FRS	Emeritus Courtauld, Professor of Biochemistry
Mr D Fawcett	Urologist
Mr G Branagan	Colorectal Surgeon
Dr J Fowler	Cardiologist
Mr A Mirnezami	Colorectal Surgeon
Dr A Kirkham	Radiologist
Mr A Belgaumkar	Hepatobiliary Surgeon
Mrs S Crane	Pelican Chief Executive

Charity Funds

The Pelican Reserves Policy 2016 - 2017

The Trustees discussed the Reserves Policy and agreed to hold sufficient reserves to allow the Charity and its associated activities to continue for 18 months (£900,000), as per the recommendations of the Charity Commission. In addition, the Charity will maintain additional funds to complete outstanding research.

Currently the Pelican Cancer Foundation holds £1.5M in reserves. The Charity aims to use a proportion of these funds over the next three years to support the growth of its research and education. This will ensure that the Charity is able to continue to fund ground-breaking clinical research and disseminate results via its education programme to improve patient treatments.

The Charity has committed to grants valued at £87,833 which are currently outstanding. The Charity has a policy of providing seed funding for new projects which can take longer to get off the ground. We do not pay grants until projects are underway or research staff have been engaged.

Risk

A risk assessment is continuously monitored and presented at Trustee meetings.

- a. As in previous years the highest risks identified related to the uncertainty of future income. An annual budget is developed and approved by the trustees. Management accounts are reviewed regularly and by the trustees quarterly.
- b. Restrictions in NHS budgets make it harder for clinicians to get financial support for training and professional development (max £500 per person per year).

Public Benefit

The Trustees confirm that they have complied with their duty in section 17 of the Charities Act 2011 and due regard to the public benefit guidance published by the Commission in determining the activities undertaken by the Charity. The Trustees report sets out how the Charity addresses the public benefit requirement.

AIM, OBJECTIVES AND ACTIVITIES

Charitable Objects

For the public benefit to advance research education and treatment of cancer in particular but not exclusively bowel cancer, other pelvic malignancies, liver cancer and related diseases.

THE PELICAN CANCER FOUNDATION

TRUSTEES REPORT

FOR THE YEAR ENDED 31 MARCH 2017

Vision - what do we want to do in 2017 and beyond?

Help cancer patients live for longer with a better quality of life. Help cancer clinicians advance their understanding and treatment of cancer.

Mission - why do we exist/what do we want to achieve?

Help clinicians advance their skills and understanding of precision treatment for bowel, liver and urology cancers. Support research and researchers investigate innovative precision cancer treatments. Disseminate knowledge of innovative research and advances in precision treatment.

Achievements

The long-term achievement of Pelican Cancer Foundation is the radical change in rectal cancer management: the widespread international adoption of Total Mesorectal Excision (TME) as the gold standard surgical treatment for bowel cancer. Added to this is the development of multi-disciplinary treatment: the integration of imaging with MRI as a guide to surgery, individualised adjuvant therapy planning, precise surgery and histopathological analysis has all helped patients to live better for longer. These are all areas that Pelican has pioneered and, through advanced training and development, has helped to embed in NHS practice in England and Wales.

In prostate cancer the charity seed funded the early research into focal therapies for prostate cancer and the use of MRI for more precise early diagnosis. Both of these are having a worldwide influence on the management and treatment of prostate cancer.

ACHIEVEMENTS AND PERFORMANCE 2016 - 2017

Courses & Education

The Charity is fortunate to have exceptional teaching facilities that are used to host workshops and conferences for surgical cancer specialists and their multi-disciplinary teams. The Charity organised 19 conferences and workshops throughout the reporting period, with 945 delegates attending. Course fees, industry sponsorship, education grants and donations provided income to meet the course costs and administration.

The SPECC | Significant Polyp and Early Colorectal Cancer National Development programme continued in this period. A series of free workshops which the Charity has taken around England to help multidisciplinary bowel cancer teams advance their understanding and practice. At the same time the Charity delivered a curriculum of exciting and challenging multi-disciplinary meetings and courses for bowel, liver and prostate cancer.

Support for Hampshire Hospitals NHS Foundation Trust (HHFT)

Pelican Cancer Foundation offices are located adjacent to HHFT, many of our speakers come from the hospital and surgical filming is streamed from the hospital's operating theatres for courses.

Every person diagnosed with cancer is discussed by a multidisciplinary cancer team (MDT). Every week Pelican freely hosts 11 MDT meetings in our purpose built room. The Charity also hosts research meetings, further clinical meetings and video conferences for the hospital. Every year there are over 4,500 cancer patients discussed in these meetings.

Medical Research Activity

Pelican Cancer Foundation is a member of the Association of Medical Research Charities and a Partner Organisation with the National Institute of Health Research. All research is selected and monitored in line with AMRC recommendations and the oversight of the Pelican Research Review Panel (PRRP).

THE PELICAN CANCER FOUNDATION
TRUSTEES REPORT
FOR THE YEAR ENDED 31 MARCH 2017

The Charity advertised research funding to over 2,000 cancer specialists in August 2016 and received 12 full applications. After the full process of grant review and consideration funding was agreed for 2 new projects, a further 3 new studies under review, and continued funding for MERCURY II.

A number of papers were published in high impact professional journals and both the faculty and fellows presented their research at international meetings.

Professor Heald

Professor Heald is an international advocate advancing precision surgery for bowel cancer and travelled widely in this period.

Professional fees

During the financial year Professor Heald received professional fees totalling £15,000 for representing the Charity worldwide, speaking at international conferences and disseminating research findings on behalf of Pelican Cancer Foundation.

Income generation and Fundraising

The Charity was particularly grateful to all those supporters who gave donations to the Charity and attended charitable events as the Charity's research would not be possible without this income.

Remuneration

As a charity, Pelican relies heavily on donated funds and the ongoing support of volunteers and funders; it is important to us that these resources are used to maximum effect.

In order to run Pelican as an efficient and effective organisation able to deliver quality services, Pelican employs 7 people - some part time.

Staff costs (salaries and pension contributions) make up a large proportion of the annual cost of running Pelican. Managing staff costs whilst ensuring that the charity has the appropriate mix of skills and expertise to achieve its objectives is an important part of ensuring the ongoing success and viability of the Charity. The total staff costs for Pelican in 2016/17 was £191,905.

The median salary point (FTE) for the organisation as a whole is now £25,707. The Chief Executive Officer (CEO), Sarah Crane, is the highest paid member of staff. Her remuneration package consists of an annual salary plus pension contribution.

Human Resources

The Charity has a small staff and during the year there were no outstanding HR issues.

FINANCIAL REVIEW

In this previous period the Pelican Reserves Committee was established (Jonathan Wood, Graham Morris and Sarah Crane). It was agreed that the bulk of the reserves would be invested with Ruffer.

THE PELICAN CANCER FOUNDATION
TRUSTEES REPORT
FOR THE YEAR ENDED 31 MARCH 2017

PLANS FOR THE FUTURE

Pelican Teaching and Meetings

- Provide education and development opportunities for surgeons and multi-disciplinary cancer teams
- Complete the SPECC (Significant Polyp and Early Colorectal Cancer Programme) by January 2018
- Run courses of interest and high standard for clinicians
- Attract high profile and influential faculty and presenters
- Provide expert and professional support for meetings and seminars booked through Pelican
- Market courses widely, effectively and economically
- Raise sufficient funds for this activity to be self-supporting
- Keep accurate records of all activity

Research

- Develop a respected and meaningful research portfolio for advances in precision surgery for pelvic region and liver cancers
- Advertise annual grant rounds for studies that advance precision treatment of cancer
- Ensure good governance of the grant giving and studies in the Pelican research portfolio
- Develop training and development where Pelican research projects have led to a change in surgical practice
- Keep accurate records of all research, publications and presentations
- Seek funding opportunities to support the research activity

Raise Awareness of

- The Charity's achievements, new courses and research as appropriate
- The importance of precise cancer treatment, with an emphasis on surgery
- Aspects of the Total Mesorectal Excision concept, which form the core of many current advances in the management of rectal cancer
- Prostate cancer treatment, in particular over diagnosis and over treatment
- The exceptional work of the Charity

Publicity

- Seek opportunities to write articles or respond to stories in the media
- Raise the profile of the Charity
- Maintain informative and relevant websites
- Produce regular newsletters for supporters
- Encourage local press reporting on activity
- Increase the social media activity and internet profile of Pelican

Pelican Administration

- Ensure good human resources policies and practices that support and encourage all those who work for the Pelican team
- Develop good accounting practice that is transparent and open
- Collaborate with other charities to improve outcomes

Fundraising

- Raise sufficient funds to support the above activities
- Adhere to best practice in fundraising policies and activities
- Encourage a broad range of fundraising methods that are cost effective

THE PELICAN CANCER FOUNDATION

TRUSTEES REPORT

FOR THE YEAR ENDED 31 MARCH 2017

STATEMENTS OF TRUSTEES' RESPONSIBILITIES IN RELATION TO THE FINANCIAL STATEMENTS

The trustees are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales/Northern Ireland requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of the incoming resources and application of resources of the Charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP 2015 (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the Charity and financial information included on the Charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

In so far as the trustees are aware:

- there is no relevant audit information of which the charitable company's auditor is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

AUDITORS

taylorcocks have expressed their willingness to continue in office and a resolution to reappoint them will be proposed at the annual general meeting.

This report was approved by the Board of Trustees on19/9/2017



PROFESSOR R HEALD CBE

PELICAN CANCER FOUNDATION

INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF THE PELICAN CANCER FOUNDATION *(continued)*

FOR THE YEAR ENDED 31 MARCH 2017

We have audited the financial statements of The Pelican Cancer Foundation for the year ended 31 March 2017 which comprise the Statement of Financial Activities, the Balance Sheet and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland."

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

RESPECTIVE RESPONSIBILITIES OF THE TRUSTEES AND AUDITORS

As explained more fully in the Trustees' Responsibilities Statement set out in the Trustees Report, the trustees (who are also the directors of The Pelican Cancer Foundation for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's (APB) Ethical Standards for Auditors.

SCOPE OF THE AUDIT OF THE FINANCIAL STATEMENTS

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the charitable company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the trustees; and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the annual report to identify material inconsistencies with the audited financial statements and to identify any information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in course with performing the audit. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

OPINION

In our opinion:

- the financial statements give a true and fair view of the state of the charitable company's affairs as at 31 March 2017 and the charitable company's incoming resources and application of resources, including its income and expenditure, for the year then ended;
- the financial statements have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- the financial statements have been prepared in accordance with the Companies Act 2006.

PELICAN CANCER FOUNDATION

INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF THE PELICAN CANCER FOUNDATION *(continued)*

FOR THE YEAR ENDED 31 MARCH 2017

OPINION ON OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006


In our opinion based on the work undertaken in the course of the audit:

- the information given in the Trustees' Annual Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Trustees Annual Report has been prepared in accordance with applicable legal requirements.

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustee's remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the Trustees' Annual Report.



James Blake ACA (Senior Statutory Auditor)

For and on behalf of

taylorcocks

Statutory Auditors

Office: *Portsmouth*

Date: *29/9/17*

Taylorcocks is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.

PELICAN CANCER FOUNDATION
STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2017

	Notes	Restricted Funds 2017 £	Unrestricted Funds 2017 £	Total Funds 2017 £	Total Funds 2016 £
Incoming Resources					
Incoming resources from generated funds:					
Voluntary income	2	22,137	260,438	282,575	103,021
Investment income	2	-	147	147	559
Trust income	2	54,750	20,000	74,750	26,400
Legacy income	2	-	-	-	75,763
Income resources from charitable activities:					
Courses	2	8,000	107,010	115,010	113,849
Other income:					
Refund of Corporation Tax		-	-	-	28,056
Total incoming resources		<u>84,887</u>	<u>387,595</u>	<u>472,482</u>	<u>347,648</u>
Resources expended					
Cost of generating funds	3	-	142,794	142,794	92,636
Charitable activities					
Research expenditure	3	74,700	90,840	165,540	169,865
Course costs	3	10,634	200,777	211,411	226,581
Total Resources expended		<u>85,334</u>	<u>434,411</u>	<u>519,745</u>	<u>489,082</u>
Net incoming resources for the year		(447)	(46,816)	(47,263)	(141,434)
Unrealised gains on revaluation of investment assets					
		-	132,377	132,377	(63,371)
Transfer between funds					
		3,543	(3,543)	-	-
Net movement of funds		<u>3,096</u>	<u>82,018</u>	<u>85,114</u>	<u>(204,805)</u>
At 31 March 2016		24,520	1,385,330	1,409,850	1,614,655
At 31 March 2017		<u>27,616</u>	<u>1,467,348</u>	<u>1,494,964</u>	<u>1,409,850</u>

All incoming resources and resources expended derive from continuing activities.

The notes on pages 11 to 21 form part of these financial statements.

PELICAN CANCER FOUNDATION

BALANCE SHEET

FOR THE YEAR ENDED 31 MARCH 2017

	Notes	2017		2016	
		£	£	£	£
Fixed assets					
Tangible assets	7		4,821		4,548
Investments	8		1,216,157		1,063,650
Current assets					
Accounts receivables		15,302		28,789	
Prepayments and other debtors		20,654		36,765	
Cash at bank and in hand		395,032		412,495	
		<u>430,988</u>		<u>478,049</u>	
Creditors: amounts falling due within the year					
Accounts payables		37,053		23,150	
PAYE, NI & Pension creditors		7,300		11,005	
Accruals		4,800		25,692	
Grants pledged	9	87,833		50,050	
Deferred income		20,016		26,500	
		<u>157,002</u>		<u>136,397</u>	
Net current assets			273,986		341,652
Total assets less current liabilities			<u>1,494,964</u>		<u>1,409,850</u>
Funds					
Restricted	10		27,616		24,520
Designated	11		1,117,255		1,200,000
General	11		350,093		185,330
			<u>1,494,964</u>		<u>1,409,850</u>

The financial statements have been prepared in accordance with the accounting policies set out in notes to the accounts and comply with the charity's governing document, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland published on 16 July 2014 (as amended by Update Bulletin 1 published on 2 February 2016).

These financial statements were authorised for issue and approved by the Trustees on 17/9/2017

PROFESSOR R HEALD CBE



Company registration number: 07264864

The notes on pages 11 to 21 form part of these financial statements.

PELICAN CANCER FOUNDATION
NOTES TO FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2017

1. ACCOUNTING POLICIES

Charity information

The Pelican Cancer Foundation is a charitable company incorporated in England and Wales. The registered office is The Ark, Dinwoodie Drive, Basingstoke, Hampshire, RG24 9NN.

Accounting conventions

These accounts have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102"), "Accounting and Reporting by Charities" the Generally Accepted Accounting Practice as it applies from 1 January 2015. The charity is a Public Benefit Entity as defined by FRS 102.

The accounts are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest pound.

The accounts have been prepared under the historic cost convention. The principal accounting policies adopted in the preparation of the financial statements are set out below.

These accounts are for the year ended 31 March 2017 are the first accounts of The Pelican Cancer Foundation prepared in accordance with FRS 102. The date of transition to FRS 102 was 1st April 2015. The reported financial position and financial performance for the previous period are not affected by the transition to FRS 102.

Going Concern

At the time of approving the accounts, the trustees have a reasonable expectation that the charity has adequate resources to continue in operation existence for the foreseeable future. Thus the Trustee continue to adopt the going concern basis of the accounting in preparing the accounts.

Incoming Resources

Charitable trading activities

Income from courses, meetings, reimbursed travel is included in incoming resources in the period in which relevant expenditure is incurred.

Grants are credited to income in the year they are received. Specific grants are matched with related expenditure and charged to the periods in which the expenditure is incurred.

Fundraising income

Fundraising income is recognised in the period in which the fundraising event takes place.

Donations and legacies

Income from donations is included in incoming resources when receivable. For legacies, entitlement is the earlier of the charity being notified of an impending distribution or the legacy being received.

Interest receivable

Interest is included when receivable by the charity.

PELICAN CANCER FOUNDATION
NOTES TO FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2017

Resources expended

Resources expended are included in the Statement of Financial Activities on an accruals basis, inclusive of any VAT which cannot be recovered.

Certain expenditure is directly attributable to specific activities and has been included in those cost categories. Wages are split on a proportion of time spent on activities. Certain other costs, which are attributable to more than one activity, are apportioned across cost categories on the basis of the proportion of resource allocated to those activities.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments' of FRS102 to all of its financial instruments.

Financial instruments are recognised in the charity's statement of financial position when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financial transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basis financial liabilities

Basic financial liabilities, included creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financial transaction, where the debt instruments is measured at the present value of the future receipts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of the operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

De-recognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

PELICAN CANCER FOUNDATION
NOTES TO FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2017

Taxation

The charity is considered to pass the tests set out in paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purpose. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to extent that such income or gains are applied exclusively to charitable purpose.

Critical accounting estimates and judgments

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of the assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may vary from these estimated.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revision to accounting estimates are recognised in the period in which the estimates are revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The trustees have considered whether there are critical judgements required in the preparation of these accounts and have concluded that there are none required disclosure.

Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost, being purchase price plus any incidental costs of acquisition, less depreciation. Depreciation is provided at rates calculated to write off the cost less estimated residual value of each asset over its expected useful life, as follows:

Computers	-	25% straight line
Equipment	-	25% reducing balance

Investments

Investments listed on a recognised stock exchange are stated at mid market value in the balance sheet. All movements in value arising from changes and revaluations are included in the Statement of Financial Activities.

Pension costs

The charity offers employees the opportunity to participate in a group pension scheme. Contributions paid by the charity during the year are disclosed within the accounts in accordance with the applicable accounting standards.

Fund accounting

Funds held by the charity are either

- *Unrestricted general funds* - these are funds which can be used in accordance with the charitable objects at the discretion of the trustees.
- *Designated funds* - these are funds set aside by the trustees out of unrestricted general funds for specific future purposes or projects.
- *Restricted funds* - these are funds that can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each restricted fund is included in the note 10 to the financial statements.

PELICAN CANCER FOUNDATION
NOTES TO FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2017

2. INCOMING RESOURCES

	Restricted funds		Unrestricted funds		Total funds	
	2017	2016	2017	2016	2017	2016
	£	£	£	£	£	£
<u>Income resources from generating funds</u>						
Voluntary Income	22,137	14,820	260,438	88,201	282,575	103,021
Investment Income	-	-	147	559	147	559
Trust Income	54,750	21,700	20,000	4,700	74,750	26,400
Legacy Income	-	-	-	75,763	-	75,763
<u>Income resources from charitable activities</u>						
Research	-	-	-	-	-	-
Courses	8,000	-	107,010	113,849	115,010	113,849
<u>Other Income</u>						
Refund re R & D claim	-	-	-	28,056	-	28,056
Total costs	84,887	36,520	387,595	311,128	472,482	347,648

3. RESOURCES EXPENDED

	Cost of generating funds	Research expenditure	Course costs	Total 2017	Total 2016
	£	£	£	£	£
Training courses	-	-	90,357	90,357	76,353
Research expenditure	-	106,293	-	106,293	89,261
Wages and salaries	70,506	34,155	70,046	174,707	194,140
Facilities costs	8,282	8,282	16,564	33,128	36,153
Consultancy and professional fees	14,140	6,698	13,395	34,233	37,426
Fund raising costs	27,499	-	-	27,499	15,000
Website and promotional	1,989	-	1,989	3,978	3,798
Support costs	20,378	10,112	19,060	49,550	36,951
Total costs	142,794	165,540	211,411	519,745	489,082

PELICAN CANCER FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2017

3. RESOURCES EXPENDED (continued...)

	2017	2016
	£	£
Analysis of support costs		
Depreciation	1,560	874
IT costs	6,834	7,017
Governance costs	20,415	12,019
Audit fees	4,800	4,225
Bank fees	2,765	2,824
Other support costs	13,176	9,992
	49,550	36,951

Certain expenditure is directly attributable to specific activities and has been included in those cost categories. Wages are split on a proportion of time spent on activities. Certain other costs, which are attributable to more than one activity, are apportioned across cost categories on the basis of the proportion of resource allocated to those activities.

4. STAFF COSTS AND TRUSTEES' REMUNERATION

	2017	2016
	£	£
Staff costs and trustee's remuneration		
Wages and salaries	143,385	153,070
Social security	9,380	13,464
Pension costs	39,140	27,606
	191,905	194,140

No employee earned more than £60,000 in the year (2016 – no employee earned more than £60,000).

5. STAFF NUMBERS

The average number of employees during the year was made up as follows:

	2017	2016
	No	No
Wages and salaries	5	4

6. NET INCOMING RESOURCES FOR THE YEAR

This is stated after charging:

	2017	2016
Auditors remuneration – as auditor	4,800	4,225
Depreciation	1,560	874

PELICAN CANCER FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2017

7. TANGIBLE FIXED ASSETS – FOR CHARITIES OWN USE

	Computers £	Equipment £	Total £
Cost			
At 1 April 2016	94,232	26,051	120,283
Additions	1,833	-	1,833
Disposals	(14,004)	(1,546)	(15,550)
At 31 March 2017	<u>82,061</u>	<u>24,505</u>	<u>106,566</u>
Depreciation			
At 1 April 2016	90,061	25,674	115,735
Depreciation charge	1,351	209	1,560
Depreciation on disposals	(14,004)	(1,546)	(15,550)
At 31 March 2017	<u>77,408</u>	<u>24,337</u>	<u>101,745</u>
Net book value			
At 31 March 2017	<u>4,653</u>	<u>168</u>	<u>4,821</u>
At 31 March 2016	<u>4,171</u>	<u>377</u>	<u>4,548</u>

PELICAN CANCER FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2017

8. INVESTMENTS

	2017 £	2016 £
Market value		
At 1st April 2016	1,063,650	1,150,104
Purchases	517,579	420,923
Proceeds of sales	(264,705)	(419,108)
Gain/(loss) on disposal	22,909	12,221
(Loss)/gain on revaluation	(123,276)	(100,490)
	<u>1,216,157</u>	<u>1,063,650</u>
Cash held by investment managers	99,642	119,771
At 31 March 2017	<u><u>1,315,799</u></u>	<u><u>1,183,421</u></u>

Listed investments held at 31 March 2017 comprise the following:

	2017 £	2016 £
UK index-linked stocks	424,457	228,834
Non UK index-linked stocks	143,533	135,012
Credit and Illiquid strategies	60,701	144,527
UK equities	91,667	48,961
Equities outside the UK	344,713	341,906
Global funds	76,442	82,385
Other – Precious metals, options and forward contracts	74,644	82,025
	<u>1,216,157</u>	<u>1,063,650</u>

Investments which amounted to more than 5% of the total portfolio value as at 31 March 2017 were:

	Value £
UK (Government) 0% T-Bill 08/05/2017 GBPO.01	88,543
1.875% Treasury Index - Linked 22/11/2022	99,864
0.25% Treasury Index - Linked 22/03/2052	125,496
0.375% Treasury Index - Linked 22/03/2062	62,458
Ruffer SICAV Fixed Income Z GBP Cap	143,533
	<u>519,894</u>

PELICAN CANCER FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2017

9. ANALYSIS OF GRANTS

For the year ending 31 March 2017

	Research expenditure £
Grants pledged during the year 2016-17	
Alaker: Resp to RT	10,000
Patel: WAIST	20,000
Chand: COMET	12,000
Appleyard: Q-ABC	415
Welsh: Coagulation	5,000
Pelican Fellow up to Oct 17	48,000
Chand:RDN	2,368
Grants released due to expiry of time limits on applications	(12,000)
Grants payable charged to the SoFA in the year	85,783
	<hr/> <hr/>
	Grants pledged £
Grants payable at 31 March 2016	50,050
Grants payable charged to the SoFA in the year	85,783
Grants paid during the year	(48,000)
Grants payable at 31 March 2017	87,833
	<hr/> <hr/>

In addition to the above, the trustees had also approved the following grants to be made at 31 March 2017, but which are not accrued for within these financial statements, as the charity still had control of these funds at 31 March 2017:

	Grants approved £
Pelican Fellow: Oct 17 – Oct 19	96,000
Welsh: Coagulation	15,000
Lord: CRUMPET	20,000
Grant pledges committed, but not accrued at 31 March 2017	131,000
	<hr/> <hr/>

PELICAN CANCER FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2017

10. RESTRICTED FUNDS

At 31 March 2017, there is £27,616 carried forward within Restricted Funds (2016 - £24,520).

	At 1 April 2016 £	Incoming resources £	Outgoing resources £	Transfers £	At 31 March 2017 £
Restricted funds					
TRIGGER – Research Trial	-	14,000	14,000	-	-
SPECC – Training Programme	-	21,750	10,134	-	11,616
IMPRESS – Research Trial	2,000	-	-	-	2,000
SPECC West Midlands	500	-	500	-	-
Educational grants	-	22,137	12,137	-	10,000
3D Camera	20,020	-	23,563	3,543	-
FORECAST – Research Trial	2,000	-	-	-	2,000
Parlarc Research	-	2,000	-	-	2,000
Pelican Fellow	-	25,000	25,000	-	-
Total Restricted funds - 2017	24,520	84,887	85,334	3,543	27,616

At 31 March 2016, there was £24,520 carried forward within Restricted Funds (2015 - £nil).

	At 1 April 2015 £	Incoming resources £	Outgoing resources £	Transfers £	At 31 March 2016 £
Restricted funds					
TRIGGER – Research Trial	-	5,000	5,000	-	-
SPECC – Training Programme	-	7,000	7,000	-	-
IMPRESS – Research Trial	-	2,000	-	-	2,000
SPECC West Midlands	-	500	-	-	500
3D Camera	-	20,020	-	-	20,020
FORECAST – Research Trial	-	2,000	-	-	2,000
Total Restricted funds - 2016	-	36,520	12,000	-	24,520

PELICAN CANCER FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2017

11. UNRESTRICTED CHARITY FUNDS 2016

	At 1 April 2016 £	Incoming resources £	Outgoing resources £	Transfers £	At 31 March 2017 £
Designated funds					
Contingency reserve	600,000	-	-	-	600,000
Research & Education commitments	500,000	-	(82,745)	-	417,255
Fixed asset fund	100,000	-	-	-	100,000
Total Designated funds	<u>1,200,000</u>	<u>-</u>	<u>(82,745)</u>	<u>-</u>	<u>1,117,255</u>
General funds	185,330	519,972	(351,666)	(3,543)	350,093
Total Unrestricted funds - 2017	<u>1,385,330</u>	<u>519,972</u>	<u>(434,411)</u>	<u>(3,543)</u>	<u>1,467,348</u>
	At 1 April 2015 £	Incoming resources £	Outgoing resources £	Transfers £	At 31 March 2016 £
Designated funds					
Contingency reserve	600,000	-	-	-	600,000
Research & Education commitments	750,000	-	(250,000)	-	500,000
Fixed asset fund	100,000	-	-	-	100,000
Total Designated funds	<u>1,450,000</u>	<u>-</u>	<u>(250,000)</u>	<u>-</u>	<u>1,200,000</u>
General funds	164,655	311,128	(290,453)	-	185,330
Total Unrestricted funds - 2016	<u>1,614,655</u>	<u>311,128</u>	<u>(540,453)</u>	<u>-</u>	<u>1,385,300</u>

PELICAN CANCER FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2017

12. ANALYSIS OF GROUP NET ASSETS BETWEEN FUNDS 2016

	Unrestricted funds		Restricted Funds £	Total £
	Designated Funds £	General Funds £		
	Fixed asset investments	1,216,157		
Tangible fixed assets	4,821	-	-	4,821
Cash at bank and in hand	17,323	350,093	27,616	395,032
Other net assets/ (liabilities)	(121,046)	-	-	(121,046)
	<u>1,117,255</u>	<u>350,093</u>	<u>27,616</u>	<u>1,494,964</u>

13. FINANCIAL COMMITMENTS

The charity has an agreement with The Ark Conference Centre Limited to pay a proportion of costs for use of the building. The annual costs are estimated at between £35,000 and £40,000.

14. CAPITAL COMMITMENTS

There were no capital commitments, either contracted or authorised by the Trustees, at 31 March 2017.

15. CAPITAL

The company does not have a share capital as it is limited by guarantee. Each of the members is a guarantor to the extent of £1 in the event of the company being wound up whilst they are still members, in respect of debts and liabilities contracted before they ceased to be a member. There were 11 members at 31 March 2017 (2016 – 11 members).

16. RELATED PARTY TRANSACTIONS

During the year the trustee's made donations to the charity totalling £580.

During the year 2016/17 professional fees were paid to Professor R Heald CBE totalling £15,000 (2016 – £15,000). At the year end the charity owed Professor R Heald CBE £3,750 (2016 - £nil).